<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01834742</url>
  </required_header>
  <id_info>
    <org_study_id>NER1006-01/2011 (OUT)</org_study_id>
    <nct_id>NCT01834742</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects</brief_title>
  <acronym>OUT</acronym>
  <official_title>Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierrel Research Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the effect of various modified low volume polyethylene glycol
      (PEG) 3350 and ascorbic acid/ascorbate (PEG+ASC)-based gut cleansing solutions on stool
      output in healthy subjects. In addition, the study is to assess and compare the safety and
      tolerance of the modified PEG+ASC formulations following oral administration with the safety
      profile of MOVIPREPÂ®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Variable</measure>
    <time_frame>36 Hours</time_frame>
    <description>Stool weight output generated from the start of intake for the following 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PEG3350 concentration</measure>
    <time_frame>96 Hours</time_frame>
    <description>Concentration of PEG3350 in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sulphate concentration</measure>
    <time_frame>96 hours</time_frame>
    <description>Concentration of PEG3350 in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascorbic acid concentration</measure>
    <time_frame>96 hours</time_frame>
    <description>Concentration of ascorbic acid in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes concentration</measure>
    <time_frame>96 hours</time_frame>
    <description>Concentration of electrolytes in blood, urine and faeces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>96 hours</time_frame>
    <description>Spontaneouly reported adverse events will be recorded throughout the study</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Part A, arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evening dose 1 plus fixed morning dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evening dose 2 plus fixed morninf does</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evening dose 3 plus fixed morning dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moviprep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus morning dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus morning dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus morning dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed evening dose plus alternative morning dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.</description>
    <arm_group_label>Part A, arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.</description>
    <arm_group_label>Part A, arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.</description>
    <arm_group_label>Part A, arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moviprep</intervention_name>
    <description>Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.</description>
    <arm_group_label>Part A, arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.</description>
    <arm_group_label>Part B, arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.</description>
    <arm_group_label>Part B, arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.</description>
    <arm_group_label>Part B, arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NER1006</intervention_name>
    <description>Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.</description>
    <arm_group_label>Part B, arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject's written informed consent must be obtained prior to inclusion.

          2. Healthy subjects with an age of 18 to 45 years.

          3. Healthy subjects need to be without any history of clinical significant
             gastrointestinal symptoms by clinical judgement and without the presence of acute
             abdominal discomfort or symptoms.

          4. Females must be surgically sterile, practicing true sexual abstinence or using an
             acceptable form of effective contraception throughout the study from the following
             list: contraceptive implants, injectables, oral contraceptives, intrauterine system
             (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method
             (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository. Hormonal
             and IUD methods of contraception must be established for a period of 3 months prior to
             dosing and cannot be changed or altered during the study. All females must have a
             negative pregnancy test at screening and check-in.

          5. Willing, able and competent to complete the entire procedure and to comply with study
             instructions.

        Exclusion Criteria:

          1. Use of laxatives in the last 12 months or colon motility altering drugs in the last 6
             months.

          2. Use of any prescription or over-the-counter (OTC) medication within 4 weeks prior to
             the first dose of investigational drug (excluding hormonal contraception, and
             occasional use of nonsteroidal anti-inflammatory drugs [NSAID], acetaminophen or
             metamizole).

          3. Donation or loss of 500 mL or more of blood within 8 weeks prior to the first dose of
             investigational drug.

          4. Any evidence of the history or presence of organic or functional gastrointestinal
             conditions (e.g. chronic constipation, irritable bowel syndrome [IBS], inflammatory
             bowel disease [IBD]).

          5. Exhibiting relevant abnormal gastrointestinal motility according to clinical judgement
             in the past or now.

          6. History or presence of any clinically significant acute illness within the 4 weeks
             prior to the first dose of investigational drug based on clinical judgement at
             screening and check-in evaluation.

          7. Known glucose-6-phosphatase dehydrogenase deficiency.

          8. Known phenylketonuria.

          9. History or evidence of any clinical significant systemic cardiovascular, hepatic,
             pulmonal, neurological, metabolic and/or renal organ dysfunction.

         10. History of clinically significant drug allergy; history of atopic allergy (asthma,
             urticaria, eczematous dermatitis), known hypersensitivity to polyethylene glycols
             and/or ascorbic acid.

         11. History or evidence of any clinically relevant electrocardiogram (ECG) abnormalities
             and hypertension.

         12. Evidence of dehydration.

         13. Any evidence for abnormal sodium or potassium levels or clinically significant other
             electrolyte disturbances.

         14. Females who are pregnant, having a positive pregnancy test at screening and/or
             admission to unit or planning a pregnancy. Females not using reliable methods of birth
             control.

         15. Clinically relevant findings on physical examination based on Investigator's
             judgement.

         16. Clinically relevant deviations of laboratory parameters from reference ranges at
             screening or check-in evaluation.

         17. Positive serology for chronic viral hepatitis or human immunodeficiency virus (HIV) at
             screening.

         18. History of drug or alcohol abuse within the 12 months prior to dosing or evidence of
             such abuse as indicated by the laboratory assays conducted during the screening or
             check-in evaluations.

         19. Subjects who are unwilling to comply with the provisions of the study protocol.

         20. Concurrent participation in an investigational drug study or participation within 3
             month of study entry.

         21. Subject has a condition or is in a situation, which in the Investigators opinion may
             put the subject at significant risk, may confound the study results, or may interfere
             significantly.

         22. Previous participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Cinca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pierrel Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pierrel Research HP-RO-SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300244</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Research HP-RO-SRL</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moviprep</keyword>
  <keyword>PEG3350</keyword>
  <keyword>Laxative</keyword>
  <keyword>Stool Output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

